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Introduction {#sec1}
============

Non-alcoholic fatty liver disease (NAFLD) is the major cause of chronic liver disease in the Western world affecting up to 30% of the adult population (70%--80% of obese and diabetics) and will become the main cause for liver transplantation by 2030 ([@bib15]). NAFLD involves conditions ranging from simple fatty liver accumulation or steatosis (triglyceride and cholesterol accumulation without significant alcohol consumption), steatosis accompanied by inflammation with or without fibrosis (steatohepatitis or NASH), progression to necrosis, cirrhosis, and hepatocellular carcinoma promoting liver-related mortality ([@bib15]). Steatosis alone is considered relatively benign, but its transition to NASH represents a key step into further liver damage, which without intervention can lead to organ transplantation. Despite its clinical relevance, the mechanisms underlying this transition are poorly understood. Indeed, there are currently no approved pharmacological interventions for NASH ([@bib39]) and effective NAFLD therapies are restricted to weight loss through lifestyle modifications ([@bib59]). Therefore, identifying factors that modulate the transition to NASH is crucial for the development of treatments directly targeting NAFLD.

The Liver X receptors (LXRs) LXRα (Nr1h3) and LXRβ (Nr1h2) are key metabolic regulators. These lipid-activated transcription factors heterodimerize with the Retinoid X receptor (RXR) to control cholesterol and fatty acid homeostasis by regulating the expression of multiple enzymes, transporters, and modulators involved in these processes ([@bib22]). In addition, LXRs modulate inflammatory and immune pathways ([@bib58]) and show anti-inflammatory and anti-fibrotic activities in experimental models of acute liver disease ([@bib5], [@bib20]). Besides ligand binding, LXR activity is regulated by post-translational modifications ([@bib6]). We and others previously showed that LXRα is phosphorylated at Ser196 (Ser198 in the human homolog) ([@bib9], [@bib61], [@bib65]) and that ligand-induced LXRα phosphorylation at this site alters its activity in a gene-specific manner in macrophage cell lines overexpressing the receptor ([@bib61], [@bib65]). However, the physiological consequences of LXRα phosphorylation, and, specifically, the impact of disrupting LXRα phosphorylation on NAFLD progression, remain unknown. Here, we report that global LXRα phosphorylation at Ser196 as a nutritional sensor that critically impacts the transition to steatohepatitis in a dietary model of NAFLD. This could open much-needed alternative therapeutic avenues for NAFLD aimed at targeting this post-translational modification of LXRα.

Results {#sec2}
=======

LXRα-S196A Mice Exhibit Enhanced Steatosis {#sec2.1}
------------------------------------------

As we previously identified in macrophages ([@bib61], [@bib65]), LXRα is phosphorylated at Ser196 (mouse) within a motif not present in LXRβ ([Figure S1](#mmc1){ref-type="supplementary-material"}A), in both mouse ([Figure 1](#fig1){ref-type="fig"}A) and human liver ([Figure S1](#mmc1){ref-type="supplementary-material"}B). To understand the impact of LXRα phosphorylation in response to a pathogenic diet, we generated a global knockin mouse carrying a homozygous serine-to-alanine mutation at Ser196 (S196A) that impairs its phosphorylation ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}C--S1E) but does not affect overall hepatic LXRα levels ([Figure S1](#mmc1){ref-type="supplementary-material"}F). On a chow diet, these mutant mice had no apparent dysmorphic phenotype and displayed similar developmental growth to matching wild-type (WT) mice (data not shown) and comparable hepatic lipids or other metabolic parameters ([Table S1](#mmc1){ref-type="supplementary-material"}).Figure 1LXRα-S196A Mice Develop Enhanced Steatosis on a High-Cholesterol Diet(A) LXRα-Ser196 phosphorylation analyzed by LXRα/β immunoprecipitation of liver homogenates and immunoblotting with a phospho-S196-LXRα-specific antibody. Global LXRα expression was assessed. Expression of Hsp90 as input loading control is shown.(B) Hepatic non-esterified fatty acids (NEFAs) and triglycerides (TGs) in mice fed an HFHC diet (n = 6/group) normalized to liver protein levels.(C) Kleiner's scores for steatosis (0--3) of liver sections (n ≥ 5/group).(D) Representative images of H&E-stained liver sections from mice fed chow or HFHC diet. Arrows point at examples of microvesicular steatosis. Scale bar, 50 μM.(E) Distribution of lipid droplets by area in H&E-stained liver sections (n = 6/group). Area distribution was compared by chi-square test for trend (p = 0.0003).(F) Hepatic gene expression in mice fed an HFHC diet (n = 6/group). Normalized data are shown relative to WT, set as 1.(G) *De novo* lipogenesis (DNL) index measured as the ratio of 16:0 (Palmitate) and 18:2 n-6 (Linoleic) content in liver (n = 6/group).(H) Hepatic fatty acid levels (n = 6/group). Data are means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005 or ^∗∗∗^p \< 0.005 relative to WT.

We previously found that cholesterol induces LXRα phosphorylation ([@bib61]); thus, we hypothesized that LXRα phospho-mutant animals respond differently to a high-fat-high-cholesterol (HFHC) diet ([@bib52]). Total body weight, plasma insulin, and glucose levels were similar between S196A and WT mice fed an HFHC diet ([Table S2](#mmc1){ref-type="supplementary-material"}). By contrast, S196A mice displayed higher levels of hepatic, but not plasma, non-esterified fatty acids (NEFAs) and triglycerides than WT mice ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}F). Indeed, enhanced micro and macrovesicular hepatic steatosis, featuring more and larger lipid droplets, were observed in S196A liver sections ([Figures 1](#fig1){ref-type="fig"}C--1E) concomitant to enhanced expression of lipid droplet genes ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Additionally, increased steatosis was associated with enhanced hepatic expression of the lipogenic transcription factor sterol response element binding protein 1 (*Srebp1c*), and other known LXR target genes involved in fatty acid synthesis (fatty acid synthase, *Fas*) ([Figure 1](#fig1){ref-type="fig"}F). In contrast, other genes such as *Cd36,* involved in fatty acid uptake were not affected. Given that plasma NEFAs, triglycerides and insulin levels do not differ between genotypes ([Figure S1](#mmc1){ref-type="supplementary-material"}F; [Table S2](#mmc1){ref-type="supplementary-material"}), increased hepatic fat accumulation in S196A mice likely results from enhanced *de novo* lipogenesis ([Figure 1](#fig1){ref-type="fig"}G) as observed in other LXR models ([@bib53]). Notably, S196A mice showed an increase in the expression of stearoyl-CoA desaturase-1 (*Scd1*) ([Figure 1](#fig1){ref-type="fig"}F), which catalyzes the production of monounsaturated fatty acids. This led us to investigate whether changes in LXRα phosphorylation alter hepatic fatty acid composition, particularly since the saturation status of fatty acids accumulating in the liver during steatosis are thought to modulate the development of fatty liver and its progression to steatohepatitis ([@bib43]). Consistent with changes in gene expression, S196A livers showed an increase in the total amount of saturated as well as unsaturated fatty acids, specifically ω9 and certain ω6 fatty acid species ([Figure 1](#fig1){ref-type="fig"}H; [Table 1](#tbl1){ref-type="table"}). Altogether, our findings demonstrate that LXRα phosphorylation deficiency at S196 induces hepatic steatosis and alters fatty acid profiles in response to an HFHC diet.Table 1LXRα Phosphorylation Alters Hepatic Fatty Acid ProfilesWTS196Ap ValueC16:1, c95.28 ± 0.4016.85 ± 0.2970.017^∗^C18:1, c948.69 ± 2.98362.10 ± 2.6310.012^∗^C18:1, c112.29 ± 0.1362.93 ± 0.1280.011^∗^C18:2, n-610.37 ± 0.40913.11 ± 0.8500.024^∗^C18:3, n-60.49 ± 0.0280.66 ± 0.0630.054C18:3, n-30.39 ± 0.0310.47 ± 0.0430.205C20:1, n-90.38 ± 0.0140.51 ± 0.0210.001^∗^C20:2, n-60.12 ± 0.0040.14 ± 0.0040.037^∗^C20:3, n-60.53 ± 0.0280.44 ± 0.0240.048^∗^C20:4, n-63.95 ± 0.0814.27 ± 0.0490.011^∗^C20:5, n-30.15 ± 0.0060.16 ± 0.0130.559C22:5, n-30.17 ± 0.0090.17 ± 0.0100.589C22:6, n-33.15 ± 0.0553.45 ± 0.1280.078[^5]

Impaired LXRα Phosphorylation Attenuates Diet-Induced Hepatic Inflammation and Fibrosis {#sec2.2}
---------------------------------------------------------------------------------------

Diet-induced hepatic steatosis generally precedes inflammation and progression to fibrosis in experimental models ([@bib51]). Strikingly, despite the increased steatosis, S196A mice displayed less inflammation ([Figure 2](#fig2){ref-type="fig"}A) and significantly less collagen deposition than their WT counterparts ([Figure 2](#fig2){ref-type="fig"}B). This was associated with a significant decrease in the expression of several pro-inflammatory and pro-fibrotic mediators, such as *Oncostatin M* (*Osm*), *Chemokine (C-X-C motif) ligand 1* (*Cxcl1*), and *Osteopontin* (*Spp1*) and genes involved in collagen synthesis (*Col1a1* and *Tgfb2*) ([Figure 2](#fig2){ref-type="fig"}C). Only a subset of the genes analyzed was affected by the S196A mutant ([Figure 2](#fig2){ref-type="fig"}C; data not shown) highlighting the gene-specific effects the mutant receptor has on its targets. Interestingly, reduced levels of inflammatory and fibrotic genes in S196A mice were revealed mostly upon exposure to the cholesterol-rich diet, while basal expression levels on chow were largely unaffected ([Figure 2](#fig2){ref-type="fig"}D). This likely reflects a modulatory role for LXRα phosphorylation in diet-induced transcriptional responses.Figure 2LXRα-S196A Alleviates Diet-Induced Hepatic Inflammation and Fibrosis(A) Kleiner's scores for lobular inflammation (0--3) from liver sections of mice (n = 6/group).(B) Representative images of Picrosirius-Red-stained liver sections (left). Scale bar, 100 μM. Quantification of stained areas by ImageJ (n = 6/group) (right). Values are the average of positively stained area.(C) Hepatic gene expression (n = 6/group). Normalized data are shown relative to WT. Data are means ± SEM. ∗p \< 0.05, ∗∗p \< 0.005 relative to WT.(D) Hepatic gene expression in mice fed chow (n = 4/group) or HFHC diet (n = 6/group). Normalized data are shown relative to WT chow group. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005, relative to WT chow. Data are means ± SEM. ∗p \< 0.05, ∗∗p \< 0.005 relative to WT.(E) Hepatic gene expression (n = 6/group). Values shown are normalized to cyclophilin and relative to WT.

Pathways known to be implicated in the pathogenesis of lipid-induced liver damage, including apoptosis, lipid peroxidation, and macrophage content, were similar between genotypes ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C). In addition to these, prolonged adaptive endoplasmic reticulum (ER) stress is a known adaptive mechanism allowing cells to survive upon physiological changes requiring altered rates of protein folding. Notably, ER stress not only promotes steatosis, but also modulates hepatic fibrosis ([@bib12]). Expression of factors involved in the activation of ER stress, such as the UPR target gene C/EBP homologous protein *(Chop*) and the Activating Transcription Factor (*Atf3*) or the spliced X-box-binding protein-1 (*Xbp-1*), was reduced in S196A mice ([Figure 2](#fig2){ref-type="fig"}E), suggesting these animals could be protected from lipotoxicity through a reduction in ER stress. Overall, these findings demonstrate that blocking LXRα-phosphorylation at S196 attenuates lipid-induced hepatic inflammation and fibrosis despite the observed enhanced steatosis by altering the expression of key molecules in these pathways.

LXRα Phospho-Mutant Mice Are Protected from Dietary Cholesterol Accumulation {#sec2.3}
----------------------------------------------------------------------------

Free cholesterol can act as a hepatotoxic agent ([@bib37]) that induces collagen deposition in hepatic fibrosis ([@bib60]). In striking contrast to WT mice, S196A mice challenged with an HFHC diet were protected from plasma and hepatic cholesterol accumulation ([Figure 3](#fig3){ref-type="fig"}B). This was accompanied by a 20% reduction in liver weight in S196A livers compared to WT controls ([Table S2](#mmc1){ref-type="supplementary-material"}), while hepatic bile acids remained unchanged ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). Thus, we next investigated expression of genes involved in cholesterol metabolism pathways that could be altered by the LXRα phospho-mutant, some of which are already well-characterized targets of LXRα ([@bib22]). Reduced hepatic and plasma cholesterol levels were associated with decreased expression of cholesterol efflux transporter *Abcg1* ([Figure 3](#fig3){ref-type="fig"}C), reflecting a dampened response to the cholesterol-rich diet ([Figure 3](#fig3){ref-type="fig"}D). Notably, S196A mice showed a unique response to the HFHC diet regarding the upregulation of *Abcg5* ([Figures 3](#fig3){ref-type="fig"}C and 3D), a transporter mediating hepatobiliary cholesterol secretion ([@bib64]) and a well-characterized target of LXRα ([@bib22]). No difference was observed in the levels of genes involved in bile acid synthesis (*Cyp7a1*, [Figure 3](#fig3){ref-type="fig"}C) or cholesterol intestinal absorption and excretion ([Figure S2](#mmc1){ref-type="supplementary-material"}F), an important means by which LXR controls cholesterol homeostasis ([@bib22]), nor in the expression of other nuclear receptors regulating lipid metabolism ([Figure S2](#mmc1){ref-type="supplementary-material"}G; data not shown). Thus, reduced cholesterol accumulation in S196A mice is likely due to increased hepatobiliary secretion of cholesterol. Moreover, in contrast to the strong repression of the cholesterogenic transcription factor *Srebp2* and its target gene *Ldlr* by dietary cholesterol in WT mice ([Figures 3](#fig3){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}H), expression of these genes was largely unaffected by exposure to the diet in S196A mice, consistent with the unchanged hepatic cholesterol levels in these animals when challenged with the HFHC diet ([Figure 3](#fig3){ref-type="fig"}A). Overall, these differences in gene expression further reflect how the response to a cholesterol-rich diet differs between genotypes.Figure 3LXR Phosphorylation-Deficient Mice Show Reduced Cholesterol Levels in Response to an HFHC Diet(A) Plasma total cholesterol levels in mice fed a chow (n = 4/group) or an HFHC diet (n ≥ 5/group).(B) Hepatic total cholesterol levels in mice fed a chow (n = 4/group) or HFHC diet (n = 6/group). Values shown are normalized to protein levels in tissue homogenates.(C) Hepatic gene expression in mice fed an HFHC diet (n = 6/group). Normalized data are shown relative to WT.(D and E) Abcg1 and Abcg5 (D) and Srebp2 and Ldlr (E) hepatic gene expression in mice fed chow (n = 4) or an HFHC diet (n = 6). Normalized data are shown relative to WT chow group. Significance of comparisons between HFHC WT and S196A genotypes is shown in C).(F) Quantification of free oxysterols in plasma of mice fed an HFHC diet (n = 6/group).Data are means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005, ^∗∗∗∗^p \< 0.00005 relative to WT. \#\#p \< 0.005, 4 versus 6 weeks.

Intracellular cholesterol accumulation activates the unfolded protein response pathway in the ER ([@bib13]), inhibiting protein transport to the Golgi to re-establish ER function ([@bib29]). One gene linking cholesterol metabolism and ER stress is *Tm7sf2*, which not only participates in cholesterol biosynthesis as a 3β-hydroxysterol Δ14-reductase but also acts as an ER sensor by triggering anti-inflammatory pathways ([@bib7]). Consistent with a decrease in hepatic inflammation ([Figure 2](#fig2){ref-type="fig"}A), *Tm7sf2* expression was enhanced in S196A mice exposed to the diet, while other genes involved in cholesterol biosynthesis were largely unaffected ([Figure S2](#mmc1){ref-type="supplementary-material"}I). This suggests cholesterol modulation of ER stress responses, rather than cholesterol biosynthesis itself, is altered in S196A mice.

We next examined the levels of oxysterols, oxidized cholesterol derivatives some of which act as LXR ligands ([@bib26]), as these metabolites have been reported to be enhanced in NAFLD patients ([@bib24]). Interestingly, LXRα phospho-mutant mice showed significantly reduced plasma levels of most oxysterols examined ([Figure 3](#fig3){ref-type="fig"}F), consistent with the reduced signs of hepatic inflammation and fibrosis ([Figure 3](#fig3){ref-type="fig"}C). Impaired oxysterol levels could be explained by the induced *Cyp7b1* expression ([Figure 3](#fig3){ref-type="fig"}C), an enzyme involved in oxysterol catabolism ([@bib62]), in S196A mice, while enzymes implicated in oxysterol synthesis remained unaffected (data not shown). Overall, these findings suggest that inhibition of LXRα phosphorylation acts as a molecular sensor of dietary cholesterol in the progression to steatohepatitis.

LXRα-S196A Reprograms Hepatic Gene Expression and Uncovers a Diet-Induced LXRα Transcriptome {#sec2.4}
--------------------------------------------------------------------------------------------

To better understand the impact on diet-induced responses by the expression of the LXRα-S196A mutant and identify pathways sensitive to LXRα phosphorylation, we assessed global gene expression differences between WT and phospho-mutant genotypes by RNA sequencing (RNA-seq) analysis. Principal-component analysis evidenced that transcriptomes of WT and S196A mice are substantially different, especially under a cholesterol-rich diet ([Figure 4](#fig4){ref-type="fig"}A). Transcriptomic analysis revealed 668 genes whose hepatic expression is significantly altered in the mutant mice fed an HFHC diet ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S3](#mmc1){ref-type="supplementary-material"}). Remarkably, there is minimal overlap between the genes modulated by LXRα phosphorylation at S196A in chow and HFHC diets, further reflecting on a genome-wide scale the distinct response exerted by S196A mice to the metabolic challenges posed by a cholesterol-rich diet. Pathway enrichment analysis confirmed our initial findings and showed induction of genes in lipid metabolism ([Figures 4](#fig4){ref-type="fig"}D and 4E). Further interrogation of our datasets revealed that, in addition to increased expression of enzymes involved in fatty acid synthesis (*Srebf1*, *Fas*; [Figure 1](#fig1){ref-type="fig"}F), S196A expression increased the hepatic levels of enzymes involved in fatty acid elongation (Elovl3, Elovl5) and fatty acid oxidation, with a trend toward increased levels of fatty acid desaturation enzyme *Fads1* ([Figure 4](#fig4){ref-type="fig"}F). These changes likely contribute to the distinct hepatic fatty acid profile of S196A mice ([Figure 1](#fig1){ref-type="fig"}H). Interestingly, expression of most of these enzymes is severely repressed by the HFHC diet ([Figure S4](#mmc1){ref-type="supplementary-material"}A) further highlighting the modulatory role exerted by LXRα-S196A. Also corroborating previous analyses, the phospho-mutant mice showed a robust decrease in the levels of wound healing and fibrotic mediators, including several collagen genes and enzymes responsible for collagen stabilization ([Figures 4](#fig4){ref-type="fig"}D and 4G). Importantly, gene expression changes in response to an HFHC diet were substantially different in WT and S196A mice ([Figures S4](#mmc1){ref-type="supplementary-material"}B--S4D), further indicating that impaired phosphorylation of LXRα-S196 alters the susceptibility to diet-induced hepatic injury by inducing a distinct hepatic transcriptome. Moreover, expression of a subset of genes involved in extracellular matrix remodeling and tissue regeneration shown to distinguish between low-risk to mild and high-risk/severe NAFLD among pre-symptomatic patients ([@bib38]) was remarkably different between genotypes ([Figure 4](#fig4){ref-type="fig"}H). This suggests that changes in LXRα phosphorylation could alter pre-clinical NAFLD progression and emphasizes a role for Ser196-LXRα phosphorylation in the regulation of these remodeling pathways.Figure 4Changes in LXRα Phosphorylation Reprogram Hepatic Gene Expression(A) Principal-component (PC) analysis plot showing RNA-seq samples analyzed by diet and genotype.(B) Venn diagram of genes regulated by LXRαS196A compared to LXRαWT (±1.3-fold, p \< 0.05) in the indicated diets. Numbers of upregulated and downregulated genes are depicted in green and red, respectively.(C) Volcano plot of log~2~ ratio versus p value of differentially expressed genes comparing S196A and WT livers exposed to an HFHC (n = 3/group). Blue line indicates adjusted p value of 0.04 (Wald test for logistic regression).(D) GSEA analysis showing enriched pathways in S196A livers with p \< 0.5 (100 permutations) derived from HALLMARK gene sets.(E) Heatmaps of hepatic RNA-seq raw gene counts (n = 3/genotype) for fatty acid and triglyceride metabolism.(F) Fold change of hepatic RNA-seq gene counts in S196A compared to WT mice fed an HFHC diet (n = 3/genotype).(G and H) Hepatic gene expression by qPCR of top (G) upregulated and (H) downregulated genes from the RNA-seq analysis on experimentally independent WT and S196A livers (n = 6/genotype).(I) Hepatic gene expression from WT and S196A mice treated with vehicle or 50 mg/kg T0901317 (n = 4/group).Data are normalized to cyclophilin and shown relative to WT vehicle set as 1. Significance was determined using single variance ANOVA followed by Student's t test. Normalized data are shown relative to WT as mean ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005 or ^∗∗∗^p \< 0.005

Genes showing the strongest difference in expression between WT and S196A genotypes were confirmed in a separate set of mice ([Figures 4](#fig4){ref-type="fig"}I and 4J). Notably, the majority of these genes were modulated by LXRα phosphorylation only in a cholesterol-rich environment ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F) and have not been previously reported to be regulated by LXR. One such gene, *Ces1f*, is a member of the carboxylesterase 1 family that hydrolyses cholesterol esters and triglycerides and controls hepatic lipid mobilization ([@bib45], [@bib69]). Despite previous studies showing *Ces1f* is not regulated by LXR ligands ([@bib27]), we now clearly demonstrate *Ces1f* is highly sensitive to LXRα phosphorylation, preferentially in the context of an HFHC diet ([Figures 4](#fig4){ref-type="fig"}I, [S4](#mmc1){ref-type="supplementary-material"}G, and S4H). To further demonstrate the lack of *Ces1f* regulation by the LXR ligand, we treated WT and S196A mice with the LXR synthetic agonist T0901317 and assessed changes in hepatic gene expression. While both genotypes clearly exhibited responses as exemplified by the increased expression of the traditional target genes *Srebp-1c* or *Fas* ([Figure 4](#fig4){ref-type="fig"}I) and hepatic triglycerides ([Figure 6](#fig6){ref-type="fig"}C), no differences were observed in the expression of *Ces1f* between ligand-treated WT and S196A mice. Moreover, expression of phosphorylation-sensitive genes, such as *Abcg5*, did not mirror that seen in HFHC-diet-fed animals, further confirming that the effects of S196A mutation in the hepatic transcriptome of HFHC-fed animals are specific to the dietary environment.

Altogether, these data highlight the relevance of LXRα phosphorylation in revealing LXR target genes and in modulating transcriptional responses to dietary cholesterol.

Identification of l LXR Binding Sites in Dual LXRα Phosphorylation and Diet-Sensitive Genes {#sec2.5}
-------------------------------------------------------------------------------------------

We next investigated whether variation in the hepatic transcriptome observed in the S196A mice coincided with changes in chromatin modifications by chromatin immunoprecipitation sequencing (ChIP-seq) analysis. We specifically interrogated histone 3 lysine-27 acetylation (H3K27ac), a known marker for active regulatory elements in promoters and enhancers ([@bib11]) previously shown to be modulated by a fat-rich diet ([@bib55]). Remarkably, differences in H3K27 acetylation between WT and S196A identified in a different set of animals strongly overlapped with changes in gene expression ([Figures 5](#fig5){ref-type="fig"}A and 5B). Indeed, most of the H3K27 acetylation observed at genes up- and downregulated by LXRαS196A was enhanced and reduced, respectively ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). Collectively, these findings support the idea that the LXRα phospho-mutant affects gene expression partly through chromatin modifications.Figure 5LXRα Phosphorylation at S196 Affects Global H3K27 Acetylation and LXR and TBLR1 Occupancy in the Ces1f Gene(A) Volcano plot comparing differences in gene expression and H3K27Ac enriched sites shows log~2~ ratio versus --log~10~ p value of differentially expressed genes in S196A versus WT livers exposed to HFHC (n = 3). Colors show changes in H3K27Ac enrichment, and dot size depicts the p value.(B) Boxplot showing the distribution of signal changes of altered H3K27Ac sites (p \< 0.05) annotated to the upregulated (red), downregulated (blue), and unchanged (gray) genes in S196A versus WT livers by RNA-seq analysis.(C) Heatmaps of H3K27Ac ChIP-seq counts (n = 3/genotype) for Ces family genes. Location, fold change (FC), p value, and false discovery rate (FDR) value are indicated for each peak.(D) H3K27Ac ChIP-seq read alignment tracks in WT and S196A livers for Ces family gene cluster. The arrow marks location of identified DR4.

To better understand the mechanism behind the differential gene regulation resulting from LXRαS196A expression, we next examined whether changes at LXRα phosphorylation at S196 affect LXR occupancy at selected genes in the context of a cholesterol-rich diet. We chose Ces1f as an example of a phosphorylation-sensitive target gene since its expression is strongly induced in S196A livers on an HFHC diet and its locus shows significant H3K27Ac enrichment ([Figures 5](#fig5){ref-type="fig"}A, 5C, and 5D). *In silico* analysis of the Ces1f gene locus showing enhanced H3K27ac enrichment identified a degenerated DR4 sequence (AGGTCTatttAGTTCA), resembling the consensus binding site or LXRE ([@bib8]). This site was preferentially bound by LXR, but not its heterodimer partner RXR, in HFHC-fed S196A livers ([Figure 6](#fig6){ref-type="fig"}A). This was associated with increased RNA Polymerase II (Pol II) and phosho-Ser2 Pol II (pSer-Pol II) occupancy indicative of an enhanced transcriptional initiation and elongation, respectively, at the Ces1f locus ([Figure 6](#fig6){ref-type="fig"}C). In contrast, occupancy by both LXR and RXR to the well-established LXRE in Srebp-1c gene was induced ([Figure 6](#fig6){ref-type="fig"}B), as was Pol II and pSer-Pol II ([Figure 6](#fig6){ref-type="fig"}C). This shows impaired LXRαS196 phosphorylation allows the transcriptional activation of a gene containing degenerated DR4 sequences without affecting RXR occupancy.Figure 6Identification of LXR Binding Sites in LXRα Phosphorylation/Diet-Sensitive Genes(A and B) LXR, RXR, and TBLR1 occupancy at Ces1f newly identified DR4 (A) and Srebp-1c LXRE (B) sequences or a region within a gene desert (Neg S) in livers of WT and S196A mice fed an HFHC for 6 weeks (n ≥ 3/group).(C) RNA Pol II and pSer2-Pol II occupancy at Ces1f and Srebp-1c transcription start site (TSS) in livers of WT and S196A mice fed an HFHC diet (n ≥ 3).(D) LXR occupancy at Srebp-1c LXRE, Ces1f DR4, and non-specific negative sequences in livers of WT and S196A mice treated with T0901317 (+T) (n = 3/group).(E and F) pSer196-LXRα (E) and LXR occupancy (F) at Srebp1c LXRE, Ces1f putative DR4 and non-specific negative sequences in livers of WT mice fed a chow or HFHC diet for 6 weeks (n = 3/group).Results are normalized to input values. For (A)--(C), results are normalized to input values and shown relative to WT, set as 1. Data represent means ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.005 determined by Student's t test.

This LXR binding sequence was revealed by homology to previously reported LXREs identified in response to LXR ligands in the context of a chow diet ([@bib8]), as these are the only global LXR occupancy analyses available. However, ligand-induced responses may not necessarily phenocopy nuclear receptor and transcription factor binding patterns in response to a cholesterol-rich diet. Indeed, and in contrast to diet-fed animals ([Figure 6](#fig6){ref-type="fig"}A), WT and S196A female mice treated with T0901317 did not elicit differences in hepatic LXR occupancy at *Srebp-1c* LXRE and *Ces1f* DR4 sequences ([Figure 6](#fig6){ref-type="fig"}D). Moreover, pSer196-LXRα occupancy in chow and HFHC-fed livers of WT mice was reduced upon diet in the *Srebp-1c* LXRE region ([Figure 6](#fig6){ref-type="fig"}E), and a similar pattern was observed for global LXR occupancy ([Figure 6](#fig6){ref-type="fig"}F). Occupancy of the phospho-LXRα on the *Ces1f* DR4 sequence was very low ([Figure 6](#fig6){ref-type="fig"}D), reinforcing the idea that binding of LXRα on this region is enhanced preferentially by the phospho-mutant version of the receptor.

Molecular modeling studies suggest that phosphorylation of LXRα at S198 (murine S196) induces a structural change in the hinge region of the receptor ([@bib61], [@bib65]). Previously, we showed that, upon LXR ligand activation, phosphorylation affects the transcriptional activity of LXRα by modulating the binding of the NCoR corepressor to phospho-sensitive genes ([@bib61]). We were unable to detect differences in NCoR occupancy in mice exposed to the HFHC diet (data not shown), suggesting responses to cholesterol *in vivo* involve other transcriptional players whose interaction with LXRα is sensitive to its phosphorylation status. One such factor is TBLR1, which participates in nuclear receptor cofactor exchange ([@bib41]) and modulates LXR target gene expression in hepatic cells ([@bib25]). TBLR1 was found to preferentially bind to LXRα-S196A ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B) and, consistently, its occupancy at the *Ces1f* DR4 sequences was significantly enhanced in S196A livers exposed to the HFHC diet ([Figures 6](#fig6){ref-type="fig"}A and 6B) suggesting this is an important component facilitating the transcription of this gene by the LXRα phospho-mutant in the context of a cholesterol-rich diet. Collectively, these data indicate that disrupting LXRα phosphorylation at Ser196 affects diet-induced responses in liver and reveals LXR target genes partly through differential occupancy of LXR and TBLR1.

Discussion {#sec3}
==========

Despite its clinical relevance, the transition between relatively benign fatty liver steatosis to inflammatory and fibrotic steatohepatitis remains poorly understood. The role of LXRα in promoting fatty acid and triglyceride accumulation is well established and has proved a major obstacle in the development of LXR ligands as therapeutics against metabolic and cardiovascular disorders ([@bib22]). Additionally, the hepatic anti-fibrotic and anti-inflammatory actions of LXRs in animal models of advanced fibrosis shed light into additional pathways these receptors modulate toward advanced steatohepatitis ([@bib5], [@bib63]). Based on the idea of the beneficial effects of reversing hepatic lipid accumulation, pharmacological antagonism of LXRs has been proposed as an effective therapy against NAFLD. For instance, a liver-selective LXR inverse agonist SR9238 was shown to suppress hepatic fatty acid synthesis and lipid accumulation leading to alleviated hepatic inflammation and fibrosis in an obese rodent model ([@bib18], [@bib19]). However, it remained to be defined how LXR affects the transition to early fibrotic inflammatory stages of NAFLD in the context of an established fatty liver, which is more clinically relevant. Previous studies focused their efforts at examining changes in LXRα expression and reported induced levels of LXRα present in steatotic, inflammatory, and fibrotic livers ([@bib2], [@bib35]). These could, however, represent an adaptive or a maladaptive or pathogenic response to the ongoing cellular and molecular changes. Others studies, however, have shown that LXRα is the only nuclear receptor whose expression is unaffected during progression to steatohepatitis ([@bib1]). These contradictions highlight the need for further studies investigating how LXRs affect this chronic liver disease. We now propose that changes in LXRα phosphorylation play a crucial role in these transitional stages of NAFLD.

Posttranslational modifications are a powerful means by which the activity and function of nuclear receptors can be altered. However, despite the key importance of certain nuclear receptors in maintaining metabolic homeostasis, our understanding of how these modifications impact on metabolic diseases is scarce ([@bib6]). Notably, the physiological consequences of LXRα phosphorylation, sumoylation, and acetylation have only been studied *in vitro* or non-specifically in animal models by pharmacologically or genetically altering the enzymes enhancing or inhibiting these modifications ([@bib6]). To directly address the impact of LXRα phosphorylation on NAFLD progression, we have now generated a mouse model harboring an S196A mutation that disrupts LXRα phosphorylation at Ser196.

We report that disrupting Ser196-LXRα phosphorylation affects hepatic diet-induced responses by attenuating progression to steatohepatitis despite promoting lipid accumulation ([Figure 6](#fig6){ref-type="fig"}). Importantly, LXRα phosphorylation at this residue dictates transcriptional responses to an HFHC diet that promotes early stages of NAFLD. Supporting our previous data in macrophages ([@bib17], [@bib61]), we now show the S196A-LXRα mutation affects hepatic transcriptional regulation in a gene-dependent manner, rather than conferring an overall gain or loss of function. Despite abundant triglyceride and NEFA accumulation, consistent with an increased *de novo* lipogenesis gene program ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}), S196A mice exhibit significantly less hepatic inflammation and fibrosis than WT animals ([Figure 2](#fig2){ref-type="fig"}). This protective phenotype is associated with a dramatic reduction in hepatic and plasma cholesterol ([Figure 3](#fig3){ref-type="fig"}) and a robust repression of numerous pro-inflammatory and pro-fibrotic mediators, including eleven collagen species, Lysyl oxidase (LOX), and lysyl oxidase-like proteins (LOXLs) critical for collagen stabilization through irreversible crosslinking ([@bib28], [@bib36]) ([Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

Impaired LXRα phosphorylation uncovers diet-specific and phosphorylation-sensitive genes, i.e., genes responsive to changes in LXRα phosphorylation, primarily in the context of a cholesterol-rich diet ([Figures 4](#fig4){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). Additionally, these genes have not been reported to be traditional ligand-modulated LXR targets suggesting the regulation of these identified genes does not simply phenocopy ligand-induced LXR activation. For instance, previous and our own studies failed to show *Ces1f* regulation by LXR ligands ([@bib27]), whereas we now demonstrate *Ces1f* is highly sensitive to LXRα phosphorylation in early steatohepatitis ([Figures 4](#fig4){ref-type="fig"}I, [S4](#mmc1){ref-type="supplementary-material"}G, and S4H). Ces1 has been recently shown to be protective from liver inflammation and injury ([@bib66]), and its hepatic deficiency strongly increases susceptibility to cholesterol-driven liver injury ([@bib33]). However, the specific contribution by the carboxylesterase 1 family member *Ces1f* in NAFLD progression has not been addressed. In addition to *Ces1f*, other Ces1 members (*Ces1b, Ces1c, Ces1d, Ces1e*) are differentially regulated by the LXRα phospho-mutant, most of which are also only revealed to be sensitive to LXRα phosphorylation in a cholesterol-rich environment ([Figure S4](#mmc1){ref-type="supplementary-material"}G). Interestingly, the form previously shown to be induced by LXR synthetic ligands in liver, *Ces2c* ([@bib27]), does not vary in S196A mice regardless of the diet ([Figures S4](#mmc1){ref-type="supplementary-material"}G and S4H), further indicating that LXRα phosphorylation-sensitive genes in response to diet are not necessarily regulated by LXR ligands and vice versa.

The diet-sensitive-induced expression of *Ces1f* by the LXRα phosphorylation mutant associated with differential binding of LXR and TBLR1 to binding sequences in this gene. Our transcriptomic analysis showed that TBLR1 is regulated neither by changes in LXRα phosphorylation nor by exposure to the cholesterol-rich diet. Interestingly, TBLR1 activity itself is subject to regulation by posttranslational modifications ([@bib42]). This further supports that changes in posttranslational modifications are a quick, reversible, and targeted way to regulate the transcriptional machinery. It is likely that a combination of interactions in addition to TBLR1 explain the overall phenotype observed. Future proteomic analysis of cofactor complexes affected by expression of the phosphorylation mutant in NAFLD livers will be needed to dissect these interactions in detail and their impact in disease progression. This is, however, beyond the scope of our current investigation.

It is important to note that hepatic LXR occupancy at gene regulatory sites has never been explored in a cholesterol-rich diet setting before but, rather, in the context of a chow diet ([@bib8], [@bib21]). Future work will be needed to establish genome-wide binding patterns of LXR and possibly other nuclear receptors important in the regulation of hepatic metabolism in the context of this pro-fibrotic diet. Interestingly, recent studies have established that altered metabolic states promote chromatin modifications both in animal models fed fat-rich diets and in obese and diabetic individuals ([@bib31], [@bib32], [@bib68]). Some of these modifications are thought to affect chromatin accessibility and are considered to act as a "metabolic imprint" that is able to alter metabolic disease risk, such as diabetes and NAFLD. However, it was recently shown that transcriptional changes in response to a fat-rich diet that induces obesity are not associated with chromatin accessibility measured as DNase sensitivity and rather occur at pre-established regulatory regions that show differential enrichment of H3K27Ac ([@bib55]). Our findings show that HFHC diet-induced changes in hepatic gene expression in S196A mice are associated with altered H3K27Ac levels, suggesting that the LXRα phosphorylation mutant takes advantage of the altered chromatin landscape to modulate dietary transcriptional responses. We have previously shown that cholesterol induces LXRα phosphorylation at S196 *in vitro* ([@bib61]) and *in vivo*, in macrophages present in atherosclerotic mice on a fat-rich diet and in livers exposed to an HFHC diet ([@bib61]; data not shown). Additional future investigations beyond the scope of this study will be needed to further dissect the signal(s) that promotes hepatic LXRα phosphorylation at this site in animals exposed to different diets.

Overall, LXRα phosphorylation at Ser196 acts as a molecular sensor in response to nutritional challenges thus promoting a unique diet-induced transcriptome that modulates metabolic, inflammatory, and fibrotic responses key in NAFLD progression. Understanding how this and other posttranslational modifications of LXRs are modulated and their impact on liver physiology could open alternative therapeutic avenues for NAFLD.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti-LXR alphaAbcamCat\#ab41902; Clone: PPZ0412; RRID: [AB_776094](nif-antibody:AB_776094){#interref2050}Rabbit polyclonal anti-LXRα/βLaboratory of Knut R. Steffensen [@bib40]N/ARabbit polyclonal anti-pSer196 LXRα[@bib61]N/ARabbit polyclonal anti-HSP90α/βSanta CruzCat\#sc-7947; RRID: [AB_2121235](nif-antibody:AB_2121235){#intref0010}Rabbit monoclonal anti-LDLR \[EP1553Y\]AbcamCat\#ab52818; RRID: [AB_881213](nif-antibody:AB_881213){#intref0015}Mouse monoclonal anti-α-TubulinSigma AldrichCat\#T5168; RRID: [AB_477579](nif-antibody:AB_477579){#intref0020}Goat anti-Rabbit Immunoglobulins/HRPDakoCat\#P0448; RRID: [AB_2617138](nif-antibody:AB_2617138){#intref0025}Sheep anti-Mouse IgG - HRPGE HealthcareCat\#NA931; RRID: [AB_772210](nif-antibody:AB_772210){#intref0030}Rabbit monoclonal anti-TBLR1AbcamCat\#ab190796Rabbit polyclonal anti-RXRαSanta CruzCat\#sc-553; RRID: [AB_2184874](nif-antibody:AB_2184874){#intref0035}Rabbit polyclonal anti-Pol IISanta CruzCat\#sc-9001; RRID: [AB_2268548](nif-antibody:AB_2268548){#intref0040}Rabbit polyclonal anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2)AbcamCat\#ab5095; RRID: [AB_304749](nif-antibody:AB_304749){#intref0045}Rabbit polyclonal anti-Histone H3 (acetyl K27)AbcamCat\#ab4729; RRID: [AB_2118291](nif-antibody:AB_2118291){#intref0050}Rabbit Immunoglobulin GSigma AldrichCat\#I5006; RRID: [AB_1163659](nif-antibody:AB_1163659){#intref0055}Rat monoclonal anti-F4/80AbcamCat\#ab6640; RRID: [AB_1140040](nif-antibody:AB_1140040){#intref0060}**Biological Samples**Healthy human liver tissueUniversity College London-RFH BiobankREC reference 11/WA/0077**Chemicals, Peptides, and Recombinant Proteins**T 0901317Santa CruzCAS 293754-55-9Supelco 37 Component FAME MixSigma AldrichCat\#CRM47885Bradford ReagentSigma AldrichCat\#B6916T-PER Tissue Protein Extraction ReagentThermo Fisher ScientificCat\#78510DSG (disuccinimidyl glutarate)Thermo Fisher ScientificCat\#20593; CAS 79642-50-5RNase A/T1Thermo Fisher ScientificCat\#EN0551Proteinase KThermo Fisher ScientificCat\#26160RNAlaterSigma AldrichCat\#R0901; CAS 7783-20-2TRIzol ReagentThermo Fisher ScientificCat\#15596026**Critical Commercial Assays**High Fat-High Cholesterol dietTestDiet LimitedCat\#58R7Teklad chow diet (18% protein)Harlan LaboratoriesCat\#2018LabAssay CholesterolWako DiagnosticsCat\#294-65801LabAssay TriglycerideWako DiagnosticsCat\#290-63701Free Fatty Acid Assay KitAbcamCat\#ab65341Rat/Mouse Insulin ELISAMilliporeCat\#EZRMI-13KMouse Total Bile Acids Assay KitCrystal ChemCat\#80470JumpStart Taq DNA PolymeraseSigma AldrichCat\#D9307PerfeCTa SYBR Green FastMix Low ROX[Quantabio](astm:Quantabio){#intref0065}Cat\#95071qScript cDNA Synthesis KitQuantabioCat\#95047RT2 Profiler PCR Array Mouse Cytokines & ChemokinesQIAGENCat\#PAMM-150ZRT2 Profiler PCR Array Mouse Lipoprotein Signaling & Cholesterol MetabolismQIAGENCat\#PAMM-080ZStranded mRNA-Seq KitKapa BiosystemsCat\#KK8421Crosslink IP KitPierceCat\#26147Anti-FLAG M2 Magnetic BeadsSigma AldrichCat\#M8823; RRID: [AB_2637089](nif-antibody:AB_2637089){#intref0070}TUNEL Apoptosis Detection Kit - DABR&D SystemsCat\#4810-30-KTBARS Assay KitCayman ChemicalsCat\#10009055ThruPLEX DNA-seq KitTakara BioCat\#R400523QIAquick PCR Purification KitQIAGENCat\#28104**Deposited Data**Chow livers RNA-Seq raw and analyzed dataThis paperGEO: [GSE96650](ncbi-geo:GSE96650){#intref0075}HFHC livers RNA-Seq raw and analyzed dataThis paperGEO: [GSE95359](ncbi-geo:GSE95359){#intref0080}ChIP-Seq dataThis paperGEO: [GSE114104](ncbi-geo:GSE114104){#intref0085}**Experimental Models: Cell Lines**Human: HEK293T-VO,LXRα,S198A[@bib61]N/A**Experimental Models: Organisms/Strains**Mouse: WT and S196AThis paperN/A**Oligonucleotides**S196A genotyping primers: wild-type forward: GGTGTC\
CCCAAGGGTGTCCT, reverse: AAGCATGACCTGCACA\
CAAG, mutant forward: GGTGTCCCCAAGGGTGTCCGThis paperN/APrimers for qPCR, see [Table S3](#mmc1){ref-type="supplementary-material"}This paperN/APrimers for ChIP-qPCR analysis, see [Table S4](#mmc1){ref-type="supplementary-material"}This paperN/AChIP-qPCR negative sequence primersActive MotifCat\#71011**Recombinant DNA**Plasmid: LZRSpBMN-GFP, LZRSpBMN-GFP/LXRα, LZRSpBMN-GFP/S198A[@bib61]N/AMouse vector: S196A^fl/fl^This paperN/A**Software and Algorithms**DESeq2[@bib3]<https://www.huber.embl.de/users/anders/DESeq/>RRID: [SCR_015687](rridsoftware:SCR_015687){#intref0095}Gene Set Enrichment Analysis (GSEA)[@bib56]<http://software.broadinstitute.org/gsea/datasets.jsp>RRID: [SCR_003199](rridsoftware:SCR_003199){#intref0105}g:profiler[@bib46]<https://biit.cs.ut.ee/gprofiler/>MultiExperiment Viewer (MeV)[@bib23]mev.tm4.org/ RRID: [SCR_001915](rridsoftware:SCR_001915){#intref0115}Heatmapper[@bib4]<http://www2.heatmapper.ca/expression/>Venn Diagrams BEG toolLaboratory of Yves Van de Peer<http://bioinformatics.psb.ugent.be/webtools/Venn/>ImageJNational Institutes of Health<https://imagej.nih.gov/ij/> RID: SCR_003070Eli (Easy Lipids) v1.0This paper<http://www.ucl.ac.uk/muse/software>NHR-scan[@bib50]<http://www.cisreg.ca/cgi-bin/NHR-scan/nhr_scan.cgi>Integrative Genome Viewer[@bib49]<https://www.broadinstitute.org/igv/>RRID:[SCR_011793](rridsoftware:SCR_011793){#intref0150}

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Inés Pineda-Torra (<i.torra@ucl.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Generation of S196A transgenic animal models {#sec4.3.1}

The S196A floxed (S196A^fl/fl^) mouse line was generated by Ozgene Pty Ltd (Bentley WA, Australia). The genomic sequence for the murine LXRα (Nr1h3) gene was obtained from the Ensembl Mouse Genome Server (<http://www.ensembl.org//useast.ensembl.org/Mus_musculus/?redirectsrc=//www.ensembl.org%2FMus_musculus%2F>), Ensembl gene ID: ENSMUSG00000002108. The mutant fragment, located on Exon 5, contains a serine-to-alanine mutation at Ser196 introduced by site-directed mutagenesis. The point mutant exon was delivered into an intronic site inside the targeting vector, placed in opposite orientation and thus without coding capacity ([Figure S1](#mmc1){ref-type="supplementary-material"}A). The targeting construct was electroporated into the Bruce4 C57BL/6 ES cell line. Homologous recombinant ES cell clones were identified by Southern hybridization and injected into BALB/cJ blastocysts. Male chimeric mice were obtained and crossed to C57BL/6J females to establish heterozygous germline offsprings on a pure C57BL/6 background. The germline mice were crossed to a FLP Recombinase mouse line ([@bib57]) to remove the FRT flanked selectable marker cassette (Flp'd mice). Flp'd mice were then crossed with a transgenic C57BL/6 mouse strain carrying a Cre recombinase under the PGK-1 promoter ([@bib30]), resulting in the inversion and insertion of the lox-flanked mutated (loxP) vector exon 5 region in the sense orientation, and deletion of the wild-type (WT) sequence in most adult cell lineages (S196A mice) while WT matching controls carry the WT sequence in the sense orientation ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Mice were genotyped by PCR analysis of ear biopsies ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E) using the Jumpstart Taq DNA Polymerase (Sigma Aldrich).

### Animal husbandry {#sec4.3.2}

Animals were housed together in groups and maintained in a pathogen-free animal facility in a 12-h light-dark cycle in a temperature-controlled room (21.1 ± 1.1°C), with *ad libitum* access to water and food. Ten-week old female mice were used for all animal studies.

All procedures were carried under the UK's Home Office Animals (Scientific Procedures) Act 1986 and in accordance with the National Institutes of Health guidelines and the NYU Institutional Animal Care and Use Committee.

### Culture of transfected HEK293T cells {#sec4.3.3}

HEK293T cells were obtained from the ATCC and maintained in Dulbecco's modified Eagle's medium with 10% Fetal Bovine Serum (FBS) and 20 μg/ml gentamicin. Recombinant retroviruses were produced by transfecting LZRSpBMN-GFP, LZRSpBMN-GFP/LXRα, or LZRSpBMN-GFP/S198A into 293GP cells ([@bib67]). Cells infected with either the retroviral vector devoid of an LXRα sequence (VO \[vector only\]), the FLAG-tagged WT LXRα (LXRα), or phosphor mutant S198A (S198A) were sorted for green fluorescent protein expression by fluorescence-activated cell sorting. These cell lines are from human female origin and represented a pool of multiple LXRα-expressing clones.

### Human liver tissue {#sec4.3.4}

Frozen liver biopsies from adult males with colon carcinoma undergoing lobectomies were obtained from the UCL-RFH Biobank (approved by UCL--Royal Free Hospital BioBank Ethical Review Committee, 11/WA/0077). Study was approved by the local ethical board (NRES Rec Reference NC2015.020.). Each participant gave written informed consent. Storage of samples complied with the requirements of the Data Protection Act of 1998 and the Human Tissue Act of 2004.

Method Details {#sec4.4}
--------------

### Diet and drug studies and tissue collection {#sec4.4.1}

Ten-week old WT and S196A female mice were fed *ad libitum* a High Fat-High Cholesterol (HFHC) diet (17,2% Cocoa Butter, 2,8% Soybean Oil, 1,25% Cholesterol, 0,5% Sodium Cholate; AIN-76A/Clinton Diet \#4, Test Diet Limited, UK) or a chow diet (18% Protein, 6.2% Fat, 0% Cholesterol; Harlan Laboratories) for 6 or 12 weeks. For ligand activation studies, WT and S196A female mice were administered by oral gavage 50 mg/kg/day of T0901317 (Santa Cruz Biotechnology) in 0.5% methylcellulose or vehicle alone for four days.

Mice were fasted overnight prior to sacrifice. Blood was collected by cardiac puncture and plasma was aliquoted and frozen at - 80°C. Tissue was dissected, weighted and frozen at - 80°C or placed in RNAlater (Sigma Aldrich).

### Plasma and liver lipids {#sec4.4.2}

Frozen livers (50 mg) were homogenized in 250 mM sucrose, 2 mM EDTA, 10 mM Tris buffer using ceramic beads in a Minilys Tissue Homogenizer (Bertin Corp.). Triglycerides and Cholesterol were extracted with Isopropanol or Chloroform:Methanol (1:1) solutions, respectively. Non Esterified Free Fatty Acids (NEFAs) were extracted by incubating liver homogenates with 1% Triton-100X and chloroform solution. Plasma and hepatic total cholesterol, triglyceride levels (Wako Diagnostics), and NEFAs (Abcam) were determined by colorimetric enzymatic assay kits as per the manufacturer's recommendations. Hepatic lipid content was normalized to protein concentration, quantified using the Bradford Protein Assay. To this end, liver homogenates were diluted in water and incubated with Bradford Reagent (Sigma Aldrich) for 30 minutes at room temperature. Absorbance was measured at 595 nm in Microplate Reader.

### Plasma glucose and insulin {#sec4.4.3}

Blood glucose measurements (Accu-Chek, Roche Diagnostics) were taken from tail blood samples after overnight fasting. Plasma insulin concentration was measured using a rat/mouse Insulin Enzyme-Linked ImmunoSorbent Assay (ELISA) kit (Millipore), which contained a 96-well plate pre-coated with a pre-titered amount of monoclonal mouse anti-rat insulin antibodies. Quantification of immobilized antibody-enzyme conjugates was performed by monitoring horseradish peroxidase activities in the presence of the substrate 3,3′,5,5′-tetramethylbenzidine; which was measured spectrophotometrically by the increased absorbency at 450 nm, corrected from the absorbency at 590 nm. Amount of captured insulin was derived by interpolation from a reference curve generated in the same assay with reference standards of known concentrations of rat insulin (Millipore).

### Hepatic fatty acid profiles {#sec4.4.4}

Liver fatty acid content from WT and S196A mice fed a HFHC diet were assayed by gas liquid chromatography with flame ionization detection by AS Vitas (Oslo, Norway). Internal standard triheptadecanoin was added and fatty acids were methylated into methyl esters (FAMEs) with MeOH HCl and extracted with hexane. Analyses were performed on an Agilent 7890A GC and a 7683B automatic liquid sampler and flame ionization detection (Agilent Technologies, USA). Separations were obtained using a SP-2380 column. Fatty acid content was calculated based on the area percentage of peaks and response factors relative to 18:0. An external standard containing known amounts of relevant FAMEs (Supelco 37 component FAME Mix) was included in each run to correct for differences in fatty acid response factors. Results were normalized to protein content. The ratio of 16:0 to 18:2 n-6 was used to calculate a *de novo* lipogenesis index ([@bib10]). The total saturated fatty acid content was calculated as the sum of 12:0, 14:0, 15:0, 16:0, 17:0, 18:0, 20:0 and 22:0. The total unsaturated fatty acid content was calculated as the sum of ω9 (16:1 c9, 18:1 c9, 20:1 n-9), ω6 (18:2 n-6, 18:3 n-6, 20:2 n-6, 20:3 n-6, 20:4 n-6) and ω3 (18:3 n-3, 20:5 n-3, 22:5 n-3, 22:6 n-3) fatty acids.

### Hepatic bile acid quantification {#sec4.4.5}

50 mg of frozen livers were homogenized in 75% ethyl alcohol (VWR) using a Dounce homogenizer and homogenates were incubated at 50°C for 2 hours. Tubes were then centrifuged for 10 min. at 6000 x g, 4°C and supernatant was transferred onto a clean tube. Total bile acid concentration in supernatants was quantified using the Mouse Total Bile Acids kit (Crystal Chem.), as per manufacturer's instructions. Hepatic bile acids were normalized to total protein concentration, quantified using the Bradford Protein Assay.

### Oxysterol LC-MS analysis {#sec4.4.6}

Protein was precipitated from plasma with 480 pM of 24R/S hydroxycholesterol-d7 (24R/S-d7), 25-hydroxycholesterol-d6 (25-d6), 27-hydroxycholesterol-d6 (27-d6), 22R-hydroxycholesterol-d7 (22R-d7) and 1214 pM 24-25-epoxycholesterol-d6 (2425e-d6) as internal standards (Avanti Polar Lipids, Alabaster, AL, USA). Sample clean-up was conducted offline, using solid phase extraction (SPE, SilactSPE C18 100 mg, Teknolab, Ski, Norway) and dried at 30°C, re-dissolved in 2-propanol and derived ([@bib47]). Samples and calibration solutions were analyzed using an Ultimate 3000 UHPLC connected to an Advantage QqQ (both Thermo Fisher, Waltham, MA, USA) equipped with an Automatic filtration and filter back-flush SPE add-on ([@bib48]). Injection volume was 100 μL and oxysterols were retained on-line on a Hotsep Kromasil C18 100 Å 1 mm ID x 5 mm SPE. Loading mobile phase was 0.1% formic acid (FA, Sigma Aldrich, St. Louis, MI, USA) in type 1 water with a flow rate of 100 μL/min. Loading time was 2 minutes to remove excess derivatization reagent. The valve was automatically controlled by Chromeleon software. Separation of the oxysterols was achieved on an ACE 3 C18 1 mm ID x 100 mm column using a gradient. Mobile phase A and B was 0.1% FA in type 1 water and 0.1% FA in MeOH, respectively and flow rate was 75 μL/min. Gradient started at 70% B and increased to 80% B in 10 minutes, followed by an increase to 95% B in 1 minute and was hold at 95% for 10 minutes. Column temperature was 30°C. Total analysis time per sample (including injection and column reconditioning) was 27 minutes.

### Faecal cholesterol quantification {#sec4.4.7}

Dried faeces were weighed (40 mg) and grounded with a mortar and pestle. Powdered faeces were then resuspended in Phosphate Buffer Saline and solution was mixed with 5 mL of a Chloroform:Methanol (1:1) solution (VWR). Tubes were left to incubate for 10 minutes at room temperature while shaking, and were then centrifuged (3000 x g, 10 min, room temperature). Supernatants were transferred onto fresh tubes and were allowed to evaporate to dryness by placing the open tube at 65°C. Dried cholesterol remnants were then resuspended with 200 μL of isopranol + 10% Triton-100X solution (Fisher Bioreagents). Total cholesterol levels were determined using a colorimetric kit (Wako Chemicals).

### Gene expression analysis {#sec4.4.8}

Total RNA from was extracted with TRIzol Reagent (Invitrogen). Sample concentration and purity was determined using a NanoDrop 1000 Spectrophotometer and cDNA was synthesized using the qScript cDNA Synthesis Kit (Quanta). Specific genes were amplified and quantified by quantitative PCR (qPCR), using the PerfeCTa SYBR Green FastMix (Quanta) on an MX3000p system (Agilent). Primer sequences are available on Supplemental table S3. The relative amount of mRNAs was calculated using the comparative Ct method and normalized to the expression of cyclophilin ([@bib44]). Mouse Cytokines & Chemokines and Lipoprotein Signaling & Cholesterol Metabolism RT2 Profiler PCR Arrays were performed per the manufacturer's instructions (QIAGEN). Briefly, cDNA was synthesized using an RT^2^ HT first strand kit (QIAGEN), and qPCR analysis was performed using RT2 SYBR Green ROX qPCR Mastermix (QIAGEN). The relative amount of mRNAs was calculated using the comparative Ct method and normalized to an average of five housekeeping genes.

### RNA sequencing studies {#sec4.4.9}

Total RNA was extracted using TRIzol (Life technologies) and cDNA libraries were prepared using the Stranded mRNA-Seq Kit (Kapa Biosystems). Briefly, poly-A tailed RNA was purified using paramagnetic oligo-dT beads from 200 nanograms of total RNA, with a RNA Integrity Number above 7.5 as determined by the Agilent Bioanalyzer. The purified RNA was chemically fragmented and cDNA was synthesized using random primers (Kapa Biosystems). Adaptor-ligated DNA library was amplified with 12 cycles of PCR and library fragment was estimated using the Agilent TapeStation 2200.Library concentration was determined using the Qubit DNA HS assay (Life Technologies). Libraries were sequenced on an Illumina NextSeq 500, NCS v2.1.2 (Illumina) with a 43bp paired end protocol. Basecalling was done using standard Illumina parameters (RTA 2.4.11). Sequencing and pipeline analysis was performed by UCL Genomics (London, UK). Reads were demulitplexed using Illumina's bcl2fastq v2.17 and aligned using STAR v2.5.0b to the mouse GRCm38/mm10 reference sequence. Transcript abundance was estimated using Illumina's RnaReadCounter tool and differential expression analysis performed with DESeq2, which uses the Benjamin-Hochberg method for multiple testing correction ([@bib3]). Pathway enrichment analysis was performed with the Gene Set Enrichment Analysis (GSEA) software's pre-ranked module ([@bib56]) and g:profiler ([@bib46]). Top regulated genes were confirmed by qPCR on a separate set of liver samples from HFHC-fed mice. Heatmaps were created using raw gene count values with the MultiExperiment Viewer (MeV) software ([@bib23]). Clustered heatmaps of normalized gene counts were created with Heatmapper Expression tool ([@bib4]) and Venn diagrams using a BGE tool.

### Western Blotting {#sec4.4.10}

Whole liver samples were homogenized with T-PER lysis buffer (78510, Thermo Fisher Scientific) supplemented with protease and phosphatase inhibitors. Total cellular protein lysates (30μg) were loaded onto a 10% SDS-PAGE gel, electrophoresed and transferred onto a PVDF membrane. For immunoprecipitations studies, single cell suspensions from livers were immunoprecipitated with antibodies that specifically recognize human (LXRα, ab41902 Abcam) or murine (LXRα/β) ([@bib40]) receptors previously crosslinked to a column with Protein A/G Agarose following the manufacturer's protocol (Pierce). Phospho-Ser196 specific rabbit polyclonal antibody ([@bib61]), mouse α-LXRα monoclonal antibody (ab41902, Abcam), α-Hsp90 polyclonal (sc-7947, Santa Cruz), α-LDLR monoclonal (Abcam, ab52818) and anti-α-Tubulin monoclonal antibody (Sigma Aldrich, T5168) were used for immunoblotting. Anti-rabbit (PO448, Dako) or anti-mouse (NA931VS, GE Healthcare) horseradish-peroxidase-tagged antibodies were used for secondary binding and chemiluminescence (ECL 2 Western Blotting Substrate, Pierce) was used to visualize proteins.

For co-immunoprecipitation studies, HEK293T-LXRα, HEK-S198A or HEK293T-Vo cells expressing FLAG-tagged receptors as in ([@bib61]) were lysed and crude nuclear pellets were obtained. Supernatants containing nuclear proteins were incubated with FLAG antibody-conjugated agarose beads (Sigma Aldrich). Bead-associated proteins associated were eluted in TBS and immunoblotted with α-TBLR1 (ab190796, Abcam) or α-LXRα (ab41902, Abcam) antibodies.

### Histopathological analysis {#sec4.4.11}

Formalin-fixed, paraffin-embedded mouse livers were cut and stained with hematoxylin and eosin (H&E) or Picrosirius Red (Abcam) dyes. Liver histology was blindly scored by an independent histopathologist based on three semiquantitative items: steatosis (0--3), lobular inflammation (0--3) and hepatocellular ballooning (0--2) (not shown) ([@bib34]). Stained sections were scanned with NanoZoomer Digital slide scanner (Hamamatsu) and quantification of Picrosirius red-stained areas was performed using ImageJ on three independent areas per section. Data is represented as the average positively-stained percent of area of interest.

Hepatic macrophage content was assessed by quantification of F4/80 positively-stained areas (ab6640, Abcam).

### Lipid droplet identification {#sec4.4.12}

Identification and quantification of lipid droplets were made with the help of Eli (Easy Lipids) v1.0, an in-house software developed between the Multiscale Cardiovascular Engineering (MUSE) and Dr Pineda-Torra's groups at UCL. This software uses a method based on the Hough Transform ([@bib14]) for the identification of the droplets estimating the centers and radii of each of them. A final report is generated with the dimensions of the droplets (i.e., diameter and area) including a histogram describing the frequency of lipid vacuoles within specified diameter ranges.

### TUNEL staining {#sec4.4.13}

Apoptosis was detected *in situ* using a terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay as per the manufacturer's instructions (R&D Systems). Paraffin-embedded liver tissue sections were incubated with a specific TdT enzyme that incorporates biotin on exposed nucleotides after DNA fragmentation. Biotin labeling was later achieved using Streptavidin-Fluorescein and sections were imaged using the Axio Imager.A1 Digital Microscope (Zeiss). Four different areas per slide were photographed at a magnification of 200X and intensity of staining was quantified by ImageJ.

### Lipid peroxidation quantification {#sec4.4.14}

Thiobarbituric Acid Reactive Substances (TBARS) were measured in about 25 mg of frozen liver as per manufacturer's instructions (Cayman Chemicals). Briefly, lipid peroxidation was quantified by the reaction of Malondialdehyde (MDA), a product of lipid peroxidation, with thiobarbituric acid (TBA) to form a colorimetric (532 nm) product, proportional to the MDA present in the sample. Levels of MDA were normalized to total protein levels, quantified by the Bradford Assay.

### LXRα proteomic analysis {#sec4.4.15}

HEK293T cells expressing vector only (Vo), FLAG-hLXRα or FLAG-hLXRα-S198A ([@bib54]) were treated with 1 μM T0901317 for 8 hours. Cells were lysed in hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, pH 7.9) and FLAG-LXRα was immunoprecipitated from the nuclear extracts using agarose beads conjugated to FLAG antibody (Sigma). The beads were then incubated in 50 μL of TBS with 0.5 mg/ml FLAG peptide (Sigma F3165) and the proteins in the supernatant were precipitated with TCA overnight. The TCA precipitate was processed and then subjected to analysis by Multidimensional Protein Identification Technology and LTQ and LTQ orbitrap mass spectrometry ([@bib54]).

### Screening of potential LXREs {#sec4.4.16}

Screening for potential DR4 sequences was performed using the available web-based software NHR Scan (<http://www.cisreg.ca/cgi-bin/NHR-scan/nhr_scan.cgi>) ([@bib50]), which predicts potential nuclear hormone receptor binding sites on a given genomic sequence. Input sequences (gene body or sequences 30 kb upstream of transcription start site) were obtained from UCSC Genome Browser database and submitted under FASTA format. Plausible DR4 sequences were then chosen based on similarity to a published consensus sequence for the murine LXRE ([@bib8]).

### ChIP-qPCR and ChIP-sequencing {#sec4.4.17}

Fresh mouse livers (n = 3/genotype) were crosslinked with 2 mM disuccinimidyl glutarate (DSG) for 30 min, followed by 1% formaldehyde for 10 min at room temperature. The reaction was stopped with glycine at a final concentration of 0.125 M for 5 min. Single cell suspension were obtained by grinding liver pieces through a 70 μM cell strainer, and nuclei were isolated by incubating cell preparations for 10 minutes at 4°C with the following lysis buffers: Buffer 1 (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton X-100), Buffer 2 (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA), and Buffer 3 (10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-deoxycholate, and 0.5% N-Lauroylsarcosine). Pellets resuspended in 300 μL of lysis buffer 3 were sonicated for 40 cycles (30 s ON/OFF) in the UCD-300 Bioruptor (Diagenode), to generate DNA-fragment sizes of 0.2--0.5 kb. The following antibodies were used for immunoprecipitations: RXRα (sc-553, Santa Cruz), Pol II (sc-9001, Santa Cruz), Pol II-S2P (ab5095, Abcam), pS196-LXRα ([@bib61]) LXR ([@bib40]) and control rabbit IgG (I5006, Sigma Aldrich). Following RNase A (Thermo Fisher Scientific) and proteinase K (Thermo Fisher Scientific) treatment, immunoprecipitated DNA was purified using the QIAquick PCR purification kit (QIAGEN) and analyzed by quantitative real-time PCR (primer sequences are listed in [Table S3](#mmc1){ref-type="supplementary-material"}) and relative occupancies were normalized to input DNA (fold difference = 2 ^--Ct-sample-Ct-input^). To control for non-specific binding, a 82 base pair fragment in a gene desert in chromosome 6 (ActiveMotif) was used. Triplicate samples for ChIP-seq were sonicated in Diagenode Pico sonicator and immunoprecipitated with H3K27Ac (ab4729, Abcam). For library preparation, 2 ng of immunoprecipitated DNA was processed using ThruPLEX® DNA-seq Kit (Rubicon) according to manufacturer's protocols, and 50SE reads were obtained in the Illumina HiSeq 2000 (Illumina). Sequencing files (fastq files), provided by the Bioinformatics and Expression Analysis (BEA) core facility (Karolinska Institutet), and raw data from published ChIP-seq data (GSE35262) were aligned to the NCBI37/mm9 version of the mouse reference genome, using Bowtie ([@bib16]). The sequencing tags were then read and imported to the HOMER (Hypergeometric Optimization of Motif EnRichment, <http://homer.ucsd.edu/homer>) package. Peaks were identified using HOMER with default settings, and peak overlap was calculated by merging all individual peak files for every experiment. and peak heights were normalized to the total number of uniquely mapped reads and displayed in Integrative Genomics Viewer ([@bib49]) as the number of tags per 10 million tags.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analysis was performed using Prism (GraphPad) and Microsoft Excel. Unless otherwise states, data is presented as mean ± SEM. For multiple comparisons, significance was assessed by single variance ANOVA followed by Student's t test. The F-statistic (dfbetween = 3, dfwithin = 15) and the P value for the significant main effect are shown. Differences were considered significant at p \< 0.05 by a two-tailed Student t test. For distribution of liver lipid droplets, areas were compared by chi-square for trend.

Statistical details, significance and n values can be found in the figure legends.

Data and Software Availability {#sec4.6}
------------------------------

The accession numbers for gene expression RNaseq (chow and HFHC diet) and H3K27Ac ChIPSeq data reported in this paper are GEO: [GSE96650](ncbi-geo:GSE96650){#intref0175} (chow), GEO: [GSE95359](ncbi-geo:GSE95359){#intref0180} (HFHC), and GEO: [GSE114104](ncbi-geo:GSE114104){#intref0185} (ChIPSeq).

A trial of Eli v1.0 is currently available upon request on the MUSE website at UCL (<http://www.ucl.ac.uk/muse/software>).
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